Report of Foreign Issuer (6-k)
October 25 2016 - 7:27AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of
1934
For the Month of October 2016
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified
in its charter)
10 Bareket Street
KiryatMatalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
____
This
Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements
on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795 and 333-209037), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On
October 25,
201
6
,
C
a
n
-
F
i
te
B
i
o
P
h
a
r
m
a
L
t
d
. issued a press release announcing
that
it signed a distribution agreement
with Chong Kun Dang Pharmaceuticals for the
exclusive right to distribute CF102 for the treatment of liver cancer in South Korea, upon receipt of regulatory approvals, for
up to $3,000,000 in upfront and milestone payments, plus a percentage rate of royalties on net sales in the low twenties. A c
op
y
o
f
t
h
i
s
pr
ess
r
ele
a
s
e
is
at
t
a
c
h
ed
h
e
r
eto
as
Ex
h
i
b
it
99
.1
a
n
d
is
i
n
c
orpor
ated
h
e
r
ein
b
y
r
e
f
e
r
e
n
c
e
.
Exhibit Index
Exhibit
No.
|
|
Description
|
99.1
|
|
Press Release, dated October 25, 2016
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
Can-Fite
BioPharma Ltd.
|
|
|
|
Date: October 25, 2016
|
By:
|
/s/ Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
4
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2023 to Sep 2024